Psilocybin Microdosing on Cognition, Mood and Quality of Life

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
Epistemonikos ID: 6377e2a2eb15744f6eacd21796218e883a53e3ee
First added on: Mar 05, 2026